<div class="description">
<p>ViziLite Plus and OralCDx Oral cancer detection aids: to use or not to use<br>Lieutenant Colonel David C. Flint, DC, USA and Captain James T. Castle, DC, USN<br><br>Introduction<br>Oral cancer, most commonly presenting as a form of squamous cell carcinoma, continues to be a worrisome disease in the United States, with oral cancer mortality rates not significantly improved in the last 40 years. More than 30,000 people will receive a diagnosis of oral cancer this year and only 58% of those will survive 5 years. The overall 5-year survival rate of oral cancer is worse than that of cancer of the breast, colon, kidney, and uterus. Interestingly, 27% of oral cancer victims do not use alcohol or tobacco products and have no other lifestyle risk factors.<br><br>Detection of oral cancer in the earliest stages significantly improves patient survival and quality of life by limiting extensive or disfiguring surgery and the possibility of radiation treatment. The 5-year survival rate for patients with localized disease approaches 80%. For patients with distant metastases, the 5-year survival rate drops to 19%. Despite the efforts to improve oral cancer screening, approximately 50% of patients with oral cancer have evidence of regional spread to lymph nodes or local and distant metastases at time of diagnosis. Therefore, early detection of oral cancer is imperative to provide the best chance of survivability and maintaining the best quality of life.<br><br>Oral cancer detection aids that claim to help improve the chances of diagnosing oral cancer at the earliest stage possible have recently been marketed to dental professionals. ViziLite Plus with TBlue630TM (Zila Pharmaceuticals, Inc.) is an oral lesion identification and marking system that is used as an adjunct to the conventional head and neck examination. OralCDx (Oral Scan Laboratories, Inc.) is a computer-assisted method of analyzing a brush biopsy of suspected pre-cancerous and cancerous lesions in the oral cavity. This clinical up-date explores the published studies surrounding these two detection systems in an effort to help the clinician decide if these products do in fact improve the ability to detect oral cancer at its earliest stage.
</p>
<br>Subjects: Biopsy; Carcinoma; Squamous Cell; Early Detection of Cancer; Mouth Neoplasms</div>
<div class="fn value">
U.S. Navy. Naval Postgraduate Dental School</div>
<dl><dd><a rel="nofollow" class="external free" href="https://archive.org/details/07003OralCancerDetectionAids">https://archive.org/details/07003OralCancerDetectionAids</a></dd>
<dd><a rel="nofollow" class="external free" href="https://archive.org/download/07003OralCancerDetectionAids/07_-_003%20Oral%20cancer%20detection%20aids.pdf">https://archive.org/download/07003OralCancerDetectionAids/07_-_003%20Oral%20cancer%20detection%20aids.pdf</a></dd></dl>